Byondis

Byondis company information, Employees & Contact Information

Explore related pages

Related company profiles:

Driven to improve patients’ lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics. Byondis’ broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis’ expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis’ expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house. The company has a dedicated team of more than 300 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. For more information visit www.byondis.com.

Company Details

Employees
281
Founded
-
Address
Nijmegen
Phone
+31 24 679 5100
Email
in****@****dis.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
NIJMEGEN
Looking for a particular Byondis employee's phone or email?

Byondis Questions

News

Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer - Business Wire

Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer Business Wire

Byondis Appoints Louis Denis, M.D., as Chief Medical Officer - Business Wire

Byondis Appoints Louis Denis, M.D., as Chief Medical Officer Business Wire

U.S. Food and Drug Administration Issues Complete Response Letter for Byondis' [Vic-]Trastuzumab Duocarmazine - PR Newswire

U.S. Food and Drug Administration Issues Complete Response Letter for Byondis' [Vic-]Trastuzumab Duocarmazine PR Newswire

Byondis begins dosing subjects in Phase I trial of BYON4228 for solid tumours - Clinical Trials Arena

Byondis begins dosing subjects in Phase I trial of BYON4228 for solid tumours Clinical Trials Arena

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) - ASCO Publications

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) ASCO Publications

Byondis' breast cancer drug fails to bloom as FDA denies approval - Fierce Biotech

Byondis' breast cancer drug fails to bloom as FDA denies approval Fierce Biotech

Creating precision medicines for better care - Nature

Creating precision medicines for better care Nature

Byondis receives CRL from US FDA for SYD985 BLA - Pharmaceutical Technology

Byondis receives CRL from US FDA for SYD985 BLA Pharmaceutical Technology

A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines - ACS Publications

A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines ACS Publications

FDA Issues Complete Response Letter for Trastuzumab Duocarmazine in Advanced HER2+ Breast Cancer - OncLive

FDA Issues Complete Response Letter for Trastuzumab Duocarmazine in Advanced HER2+ Breast Cancer OncLive

Byondis and medac Enter Into License and Collaboration and Supply Agreements for Anti-HER2 ADC Trastuzumab Duocarmazine (SYD985) - PR Newswire

Byondis and medac Enter Into License and Collaboration and Supply Agreements for Anti-HER2 ADC Trastuzumab Duocarmazine (SYD985) PR Newswire

Model Systems in Endometriosis Research: Translation, Translation, Translation! - Frontiers

Model Systems in Endometriosis Research: Translation, Translation, Translation! Frontiers

New senior director, immuno-oncology R&D, for Byondis - PharmaLive

New senior director, immuno-oncology R&D, for Byondis PharmaLive

Byondis ready to link up to bring Herceptin-booster to market after phase 3 win - Fierce Biotech

Byondis ready to link up to bring Herceptin-booster to market after phase 3 win Fierce Biotech

Synthon Biopharmaceuticals Relaunches as Byondis - Business Wire

Synthon Biopharmaceuticals Relaunches as Byondis Business Wire

FDA Accepts Byondis' Biologics License Application for [Vic-] Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer - PR Newswire

FDA Accepts Byondis' Biologics License Application for [Vic-] Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer PR Newswire

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets - PR Newswire

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets PR Newswire

Top Byondis Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant